Intravenous injection of apelin-13 improves sensory-motor balance deficits caused by cerebral ischemic reperfusion injury in male wistar rats via restoration of nitric oxide.


Journal

Journal of chemical neuroanatomy
ISSN: 1873-6300
Titre abrégé: J Chem Neuroanat
Pays: Netherlands
ID NLM: 8902615

Informations de publication

Date de publication:
03 2021
Historique:
received: 29 08 2020
revised: 10 11 2020
accepted: 10 11 2020
pubmed: 16 11 2020
medline: 1 10 2021
entrez: 15 11 2020
Statut: ppublish

Résumé

It has been reported that apelin-13 possesses neuroprotective effects against cerebral ischemia/reperfusion injury (IRI). Disabilities in sense, movement and balance are the major stroke complications which, result in a high rate of mortality. Here, effects of intravenous (IV) injection of apelin-13 on the severity of neural death, infarct volume, neurological defects and its association with nitric oxide (NO) were investigated. A rat model of cerebral IRI was created by middle cerebral artery occlusion (MCAO) for 60 min and restoration of blood flow for 23 h. Animals were randomly assigned into six groups: sham, ischemia (MCAO), vehicle (MCAO + PBS) and three treatment groups (MCAO + apelin-13 in 10, 20, 40 μg/kg doses, IV). All injections were carried out via tail vein injection 5 min before reperfusion. Neural loss and infarct volume were evaluated by Nissl and 2,3,5-triphenyltetrazolium chloride (TTC) staining, respectively. Neurological defects were scored by standard modified criteria. Serum NO was measured by colorimetric method. Apelin-13 in doses of 20 and 40 μg/kg significantly reduced neural death, infarct volume and disturbance of sensory-motor balance compared to control and vehicle groups (p < 0.05). Serum NO levels reduced in MCAO groups compared to sham. Apelin-13 restored serum NO levels at 20 μg/kg dose (p < 0.05). Our data showed beneficial effect of IV injection of apelin-13 on sensory-motor balance defects by reducing neural death and restoration of serum NO levels. The present study shows the validity of apelin-13 in treatment of ischemic stroke in different administration methods.

Identifiants

pubmed: 33189869
pii: S0891-0618(20)30155-1
doi: 10.1016/j.jchemneu.2020.101886
pii:
doi:

Substances chimiques

Intercellular Signaling Peptides and Proteins 0
Neuroprotective Agents 0
apelin-13 peptide 0
Nitric Oxide 31C4KY9ESH

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101886

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Raheleh Gholamzadeh (R)

Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Physiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Nahid Aboutaleb (N)

Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Physiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: aboutaleb.n@iums.ac.ir.

Donya Nazarinia (D)

Department of Physiology, School of Paramedical Sciences, Dezful University of Medical Sciences, Dezful, Iran.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH